What it's for (Indications)
- Cefatrizine, a first-generation cephalosporin antibiotic, is indicated for the treatment of various bacterial infections susceptible to its antimicrobial activity.
- These typically include infections of the respiratory tract, such as bronchitis, pharyngitis, and pneumonia; skin and soft tissue infections, including cellulitis, abscesses, and folliculitis; and urinary tract infections, such as cystitis and pyelonephritis.
- It may also be used for otitis media.
- Its spectrum of activity primarily targets Gram-positive bacteria like susceptible Staphylococcus aureus (excluding MRSA) and Streptococcus species, as well as certain Gram-negative organisms such as Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis.
- The decision to prescribe cefatrizine should always be based on culture and susceptibility test results, or on strong clinical suspicion of bacterial etiology, to ensure appropriate and effective antimicrobial therapy and to mitigate the development of antibiotic resistance.
- Careful consideration of local susceptibility patterns is crucial.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of cefatrizine varies significantly depending on the specific type and severity of the infection, the patient's age, body weight, renal function, and the particular pharmaceutical formulation being utilized. For adult patients, typical oral dosages might range from 250 mg to 500 mg, administered two to four times daily. Pediatric dosages are generally calculated based on the child's body weight and age, typically provided in mg/kg. It is absolutely imperative that the exact dosage regimen, the prescribed duration of treatment, and all administration instructions are strictly adhered to as directed by a qualified healthcare professional. Self-medication, alteration of dosage, or premature discontinuation of the prescribed course can lead to suboptimal therapeutic outcomes, increase the risk of adverse effects, contribute to treatment failure, or promote the emergence of antibiotic-resistant bacterial strains. A healthcare provider will conduct a thorough evaluation of the individual patient's clinical status, infection characteristics, and medical history to determine the most appropriate and effective dosing strategy, ensuring patient safety and treatment efficacy. |
Safety & Warnings
Common Side Effects
- Like all pharmaceutical agents, cefatrizine can elicit adverse effects, although not every patient will experience them, and their severity can vary.
- Common side effects predominantly affect the gastrointestinal system, and may include nausea, vomiting, diarrhea, abdominal pain or discomfort, and dyspepsia.
- Hypersensitivity reactions, manifesting as skin rash, itching, and urticaria, are also frequently reported.
- Other less common but possible systemic adverse effects include headache, dizziness, fatigue, eosinophilia, and transient elevations in liver enzymes (e.
- g.
- , aspartate aminotransferase [AST], alanine aminotransferase [ALT]).
- More serious, albeit rare, adverse reactions that warrant immediate medical attention can include severe allergic reactions such as anaphylaxis (characterized by swelling, severe difficulty breathing, or sudden drop in blood pressure), Clostridioides difficile-associated diarrhea (CDAD), Stevens-Johnson syndrome, toxic epidermal necrolysis, renal dysfunction, and various blood dyscrasias (e.
- g.
- , thrombocytopenia, leukopenia).
- Patients should be instructed to promptly report any persistent, worsening, or severe side effects to their prescribing healthcare provider for appropriate assessment and management.
Serious Warnings
- Black Box Warning: **Serious Warnings Regarding Hypersensitivity Reactions and Clostridioides difficile-Associated Diarrhea (CDAD)** While cefatrizine, a first-generation cephalosporin, does not carry a formal FDA-mandated Black Box Warning, it is imperative for healthcare professionals and patients to be acutely aware of two significant and potentially life-threatening risks associated with its use, consistent with warnings applicable to the broader class of beta-lactam antibiotics. These serious adverse events require immediate attention and appropriate medical management. **1. Severe Hypersensitivity (Anaphylactic) Reactions:** Serious, and occasionally fatal, hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam antibiotics, including cephalosporins like cefatrizine. These reactions are more likely to occur in individuals with a history of sensitivity to multiple allergens, particularly those with a documented history of penicillin hypersensitivity. Before initiating therapy with cefatrizine, a meticulous inquiry should be made concerning previous hypersensitivity reactions to cephalosporins, penicillins, or other drugs. If an allergic reaction to cefatrizine occurs, the drug should be immediately discontinued, and appropriate emergency medical treatment (e.g., epinephrine, corticosteroids, antihistamines, airway management) must be promptly instituted. Patients should be thoroughly educated on the signs and symptoms of anaphylaxis (e.g., hives, rash, swelling of the face/lips/tongue/throat, difficulty breathing, dizziness, rapid heartbeat) and instructed to seek immediate medical attention if they experience any such symptoms. **2. Clostridioides difficile-Associated Diarrhea (CDAD):** Clostridioides difficile-associated diarrhea (CDAD) has been reported with the use of nearly all antibacterial agents, including cefatrizine, and may range in severity from mild diarrhea to life-threatening fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon, potentially leading to the overgrowth of Clostridioides difficile. C. difficile produces toxins A and B, which are major virulence factors contributing to the development of CDAD. Hypertoxin-producing strains of C. difficile cause increased morbidity and mortality, as these infections can be particularly severe, refractory to standard antimicrobial therapy, and may even necessitate colectomy in severe cases. CDAD must be considered in all patients who present with diarrhea following antibiotic use. A careful medical history is necessary, as CDAD has been reported to occur more than two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not specifically directed against C. difficile may need to be discontinued. Appropriate management protocols, including fluid and electrolyte management, protein supplementation, antibiotic treatment specifically targeting C. difficile, and surgical evaluation, should be instituted as clinically indicated.
- Several critical warnings and precautions must be considered when prescribing and administering cefatrizine.
- Patients with a documented history of hypersensitivity to penicillin or other beta-lactam antibiotics should be closely monitored due to the potential for cross-reactivity, which can range in severity from mild cutaneous reactions to life-threatening anaphylaxis.
- Clostridioides difficile-associated diarrhea (CDAD) has been reported with nearly all antibacterial agents, including cefatrizine, and its severity can vary from mild diarrhea to fatal colitis.
- Discontinuation of the drug and institution of appropriate management are necessary if CDAD is suspected or confirmed.
- In patients with pre-existing renal impairment, dosage adjustments may be required to prevent drug accumulation and potential toxicity; careful monitoring of renal function is advised.
- Prolonged or repeated use of cefatrizine, like other antibiotics, may lead to the overgrowth of non-susceptible organisms, including fungi, resulting in superinfection.
- Use during pregnancy and lactation should only be considered if clearly indicated and after a thorough evaluation of the potential risks to the fetus or infant versus the anticipated maternal benefits, as comprehensive data on its safety in these populations are limited.
- Patients should always be advised to complete the full course of treatment to optimize therapeutic outcomes and minimize the risk of bacterial resistance.
How it Works (Mechanism of Action)
Cefatrizine, similar to other beta-lactam antibiotics, exerts its potent bactericidal activity by interfering with and inhibiting bacterial cell wall synthesis. Its primary mechanism involves covalent binding to and inactivating specific enzymes known as penicillin-binding proteins (PBPs), which are integral enzymes located on the inner membrane of the bacterial cell wall. These PBPs are crucial for the transpeptidation step of peptidoglycan synthesis, a complex process essential for forming the strong, cross-linked polymeric structure that provides mechanical strength and maintains the osmotic integrity of the bacterial cell wall. By competitively binding to these PBPs, cefatrizine effectively prevents the cross-linking of adjacent peptidoglycan strands. This disruption leads to the formation of a defective, weakened, and structurally compromised cell wall. The compromised cell wall is unable to withstand the high internal osmotic pressure, ultimately resulting in rapid bacterial cell lysis and subsequent cell death. The efficacy of cefatrizine is directly dependent on its ability to maintain sufficient concentrations at the site of infection to adequately saturate and inhibit these vital PBP targets.
Commercial Brands (Alternatives)
No other brands found for this formula.